1. Lutathera

Novartis headquarters

Active ingredient: lutetium Lu 177 dotatate
Disease: gastroenteropancreatic neuroendocrine tumors
Peak sales estimate: $500 million to $2 billion
Approved: Jan. 2, 2018
Company: Novartis

The scoop: Novartis didn’t have to wait long for its $3.9 billion buyout of Advanced Accelerator Applications to pay off. Less than three months after agreeing to the pickup, the Swiss drugmaker got an FDA OK for Lutathera, which fit right into its portfolio alongside neuroendocrine tumor treatments Afinitor and Sandostatin. Since then, the product has been off to the races, racking up $56 million in third-quarter sales as part of what CEO Vas Narasimhan has called a “really explosive performance.” Through mid-October, Lutathera has been dosed 1,123 times across 85 U.S. prescribing centers. And on the reimbursement side, Novartis boasts 70% coverage of relevant lives. — Carly Helfand

Suggested Articles

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.

Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.

The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.